GlassScriptPhysician profile
Sonwoo Lee
NPI 1336168616
$3,462.40
in general payments reported to CMS, 2019-2025
22 companies · $83.82 in 2025
The $83.82 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,540 · 2020: $182 · 2021: $716 · 2022: $618 · 2023: $188 · 2024: $135 · 2025: $83.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $1,013.28 | 2019-2022 | |
| Abbvie INC. | $584.60 | 2019-2025 | |
| Amgen INC. | $562.91 | 2019-2024 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $264.85 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.49 | 2019 | |
| Ironwood Pharmaceuticals, INC | $140.87 | 2021-2023 | Linzess |
| Novo Nordisk INC | $125.74 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2021 | |
| Nestle Healthcare Nutrition INC. | $45.97 | 2021-2022 | |
| Pfizer INC. | $43.53 | 2019-2022 | |
| Vivus LLC | $42.31 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.40 | 2020-2024 | Jardiance |
| Depuy Synthes Sales INC. | $28.41 | 2021 | |
| Radius Health, INC. | $27.36 | 2020 | |
| Alexion Pharmaceuticals, INC. | $24.58 | 2023 | Strensiq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $22.19 | 2021 | |
| Allergan, INC. | $21.67 | 2019 | |
| Boston Scientific Corporation | $21.17 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.83 | 2022 | |
| Merck Sharp & Dohme LLC | $19.51 | 2019 | |
| Glaxosmithkline, LLC. | $17.34 | 2022 | |
| Gilead Sciences, INC. | $14.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonwoo Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.